Cost-effectiveness analysis comparing “PARP inhibitors-for-all” to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer

OBJECTIVES. Clinical trials evaluating universal PARP inhibitor (PARPi) frontline maintenance therapy for advanced stage ovarian cancer have reported progression-free survival (PFS) benefit. It is unclear whether PARPi maintenance therapy will universally enhance value (clinical benefits relative to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gynecol Oncol
Main Authors: Gonzalez, Rafael, Havrilesky, Laura J., Myers, Evan R., Secord, Angeles Alvarez, Dottino, Joseph A., Berchuck, Andrew, Moss, Haley A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8086124/
https://ncbi.nlm.nih.gov/pubmed/32863036
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2020.08.003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados